《大行》大摩降华润医疗(01515.HK)目标价至3元 维持“减持”评级

阿斯达克财经
14 Jul

摩根士丹利发表研究报告指,预期华润医疗(01515.HK) 上半年净利润将录得轻微增长。由于按疾病诊断相关分组(DRG)和按病种分值(DIP)两种医保支付方式的压力持续,预期基本业务利润将出现高双位数的按年下降。同时,该行将诉讼和解的一次性收益2.09亿元人民币计算在内。

大摩上调华润医疗今年每股盈测5%,但对2026及27年每股盈测分别下调8%和4%,目标价由3.3元降至3元,维持“减持”评级。(sl/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-07-11 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10